• DOI:10.1007/s11912-013-0320-x
Corpus ID: 1167562

Current and Future Treatments for Malignant Pheochromocytoma and Sympathetic Paraganglioma

@article{Jimenez2013CurrentAF,
  title={Current and Future Treatments for Malignant Pheochromocytoma and Sympathetic Paraganglioma},
  author={C. Jimenez and E. Rohren and M. Habra and T. Rich and Paola Jim{\'e}nez and M. Ayala-Ramirez and E. Baudin},
  journal={Current Oncology Reports},
  year={2013},
  volume={15},
  pages={356-371}
}

C. Jimenez, E. Rohren, +4 authors E. Baudin

Published 2013

Medicine

Current Oncology Reports

Pheochromocytomas (PHs) and sympathetic paragangliomas (SPGs) are rare neuroendocrine tumors. Approximately 17 % of these tumors are malignant, but because no molecular or histologic markers for malignancy exist, patients are often diagnosed with malignant PHs or SPGs after unresectable disease has formed. Patients with progressive metastatic tumors and overwhelming symptoms are currently treated with systemic chemotherapy and radiopharmaceutical agents such as metaiodobenzylguanidine. These… CONTINUE READING

View on Springer

ncbi.nlm.nih.gov

Save to Library

Create Alert

Cite

Launch Research Feed